small-interfering RNA | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

26,838 results for “small-interfering RNA”

Trials

View all 16159 →

Not yet recruiting

Effect of Small Interfering RNA Inclisiran on Carotid Plaques As Assessed by Carotid Ultrasound

40 participants · First posted Sep 6, 2024

Study of TD101, a Small Interfering RNA (siRNA) Designed for Treatment of Pachyonychia Congenita

1 participants · First posted Jul 16, 2008

Active, not recruiting

EphA2 siRNA in Treating Patients With Advanced or Recurrent Solid Tumors

49 participants · First posted May 4, 2012

Drugs

View all 1811 →

Small interfering RNA therapeutics (Yuhan)

Small interfering RNA prodrug therapeutics(Bianoscience)

Small interfering RNA therapeutics(Yuhan Corp.)

Organizations

View all 126 →

Rna Diagnostics, Inc.

Canada

RNA Pharma, LLC

United States

A&A SMALL CHANGES HANDYPEOPLE

United States

News

View all 8742 →

Zerlasiran Shows Cumulative Lp(a) Reduction in Phase 2 Trial

FDA Updates Leqvio Label to Recognize LDL-C Reduction Lowers Cardiovascular Event Risk

e-therapeutics' ETX-312 Shows Promise as Disease-Modifying MASH Treatment in Preclinical Studies

Page 1 of 2684